Vensica Closes $19 Million Round With Investment From Strategic Partner Merz

Feb 07, 2022•almost 4 years ago

Amount Raised

$19 Million

Tel Aviv

Description

Vensica Therapeutics ("Vensica"), a clinical stage biopharmaceutical company, has closed a $19 million investment round. Vensica executed a strategic collaboration agreement with Merz Therapeutics in 2021 and the Merz Group is participating in Vensica's financing with up to $3 million, bringing the total round to up to $19 million. The round was led by Israel Biotech Fund (IBF) with the participation of Laborie, Lew Pell, Agriline, and The Trendlines Group.

Company Information

Company

Vensica Therapeutics

Location

Tel Aviv, Tel-Aviv District, Israel

About

Vensica is a urology therapeutics company based out of Israel. The company is developing a unique platform for drug delivery for several urinary bladder indications, based on a proprietary ultrasound-assisted drug delivery system. The company was founded in 2015 by Avner Geva, (Yale, B.Sc, Technion, M.Sc) and is led and backed by medical and therapeutics leaders, including Chairman M.D., Ph.D, Nissim Darvish, Lew Pell, Laborie, Merz Pharmaceuticals, The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), and The Israel Innovation Authority.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Vensica Closes $19 Million Round With Investment From Strategic Partner Merz

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information